|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:awards
|
gptkb:Forbes_Global_2000
gptkb:Fortune_India_500
|
|
gptkbp:CEO
|
gptkb:Umang_Vohra
|
|
gptkbp:country
|
gptkb:India
|
|
gptkbp:focusArea
|
Sustainable development
Affordable medicines
Innovation in healthcare
|
|
gptkbp:foundedBy
|
gptkb:Khwaja_Abdul_Hamied
|
|
gptkbp:foundedYear
|
1935
|
|
gptkbp:headquartersLocation
|
gptkb:Mumbai
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Cipla Group
|
|
gptkbp:industry
|
Pharmaceuticals
|
|
gptkbp:ISIN
|
INE059A01026
|
|
gptkbp:listedOn
|
gptkb:Bombay_Stock_Exchange
gptkb:National_Stock_Exchange_of_India
|
|
gptkbp:manufacturingFacilities
|
gptkb:Algeria
gptkb:Bangladesh
gptkb:Belgium
gptkb:Brazil
gptkb:China
gptkb:India
gptkb:Kenya
gptkb:Mexico
gptkb:Morocco
gptkb:Myanmar
gptkb:Nepal
gptkb:South_Africa
gptkb:Sri_Lanka
gptkb:Uganda
gptkb:United_States
gptkb:Yemen
gptkb:Zambia
|
|
gptkbp:market
|
Over 80 countries
|
|
gptkbp:notableProduct
|
Respiratory medicines
Oncology medicines
Antiretroviral drugs for HIV/AIDS
Cardiovascular medicines
Diabetes medicines
|
|
gptkbp:numberOfEmployees
|
over 25,000
|
|
gptkbp:parentCompany
|
gptkb:Cipla_Limited
|
|
gptkbp:products
|
Over-the-counter medicines
Active pharmaceutical ingredients
Generic drugs
|
|
gptkbp:revenue
|
INR 21,763 crore (FY 2022-23)
|
|
gptkbp:servesArea
|
Worldwide
|
|
gptkbp:stockExchange
|
gptkb:NSE
BSE
|
|
gptkbp:stockSymbol
|
gptkb:CIPLA
|
|
gptkbp:subsidiary
|
gptkb:Cipla_Medpro
gptkb:Cipla_USA_Inc.
|
|
gptkbp:website
|
https://www.cipla.com/
|
|
gptkbp:bfsParent
|
gptkb:Cipla_Limited
|
|
gptkbp:bfsLayer
|
7
|